Jornal Vascular Brasileiro
http://www.jvb.periodikos.com.br/article/doi/10.1590/1677-5449.202500761
Jornal Vascular Brasileiro
Original Article

Tromboembolismo venoso em pacientes hospitalizados com covid-19: características clínicas e laboratoriais em três centros de assistência terciária de uma capital da Amazônia Oriental

Venous thromboembolism in hospitalized patients with COVID-19: clinical and laboratory characteristics at three tertiary care centers in a state capital in the Eastern Amazon

Ester Almeida Carneiro Rodrigues da Silva; Adson Kevin Cunha Negidio; Tiago de Oliveira Vieira; Thais Pinheiro Almeida dos Santos; Luiz Felipe Santiago Bittencourt; Paulo Martins Toscano

http://dx.doi.org/10.1590/1677-5449.202500761 J Vasc Bras, vol.25, e20250076, 2026
PDF Português
PDF English
Downloads: 0
Views: 6

Resumo

Contexto: A pandemia da covid-19 se apresenta, até o momento, como o maior desafio sanitário deste século. A fisiopatologia central implica em uma doença respiratória infecciosa causada pelo SARS-CoV-2 capaz de provocar complicações cardiovasculares nos casos mais graves, incluindo o tromboembolismo venoso (TEV).

Objetivos: Este trabalho visa caracterizar o perfil clínico e laboratorial de pacientes internados com TEV documentados durante a infecção por covid-19.

Métodos: Trata-se de um estudo observacional, longitudinal e retrospectivo de natureza analítica em que foram revisados prontuários de pacientes hospitalizados e diagnosticados por imagem com TEV em três centros médicos de assistência terciária da capital do Pará, Brasil. Dados epidemiológicos e laboratoriais foram coletados retrospectivamente em cada centro de saúde, abrangendo o período desde o primeiro caso de covid-19 registrado até julho de 2021.

Resultados: Foram identificados casos de TEV em 1,30% dos prontuários, variando de 0,60 a 2,25% nos diferentes centros. Os valores médios de idade, proteína C reativa, dímero-D, índice de massa corporal e tempo de internação foram, respectivamente, 46,35 anos, 143,23 mg/L, 4,12 µg/mL, 27,65 kg/m2 e 50,18 dias. Não foram encontradas correlações significativas (p < 0,05) entre nenhuma das variáveis estudadas e presença de TEV.

Conclusões: Parece haver alguma associação entre algumas das variáveis testadas, porém sem possibilidade de estabelecimento de relação causal. É possível que as associações epidemiológicas entre covid-19 e TEV possam ser mediadas e mais bem explicadas por eventuais fatores de confusão, como coinfecções simultâneas, condições de saúde prévias, entre outros.

Palavras-chave

biomarcadores; covid-19; embolia pulmonar; trombose venosa profunda

Abstract

Background: ATo date, the COVID-19 pandemic constitutes the greatest health care challenge of the century. Its central pathophysiology involves an infectious respiratory disease caused by the SARS-CoV-2 virus with potential in the most severe cases to provoke cardiovascular complications, including venous thromboembolism (VTE).

Objectives: This study describes the clinical and laboratory characteristics of hospitalized patients with VTE confirmed during a COVID-19 infection.

Methods: This is an observational, longitudinal, and retrospective analytical study based on review of the medical records of patients admitted to three tertiary centers in the capital of Pará state, Brazil, with VTE diagnosed by imaging. Epidemiological and laboratory data were collected retrospectively at each health center, covering the period starting when the first case of COVID-19 was recorded and ending in July 2021.

Results: VTE cases were recorded in 1.30% of medical records, with percentages varying from 0.60% to 2.25% at the different centers. Mean age, C-reactive protein, D-dimer, body mass index, and length of hospital stay were 46.35 years, 143.23 mg/L, 4.12 µg/mL, 27.65 kg/m2, and 50.18 days, respectively. No significant correlations (p < 0.05) were observed between presence of VTE and any of variables studied.

Conclusions: There appeared to be associations between some of the variables tested, but it was not possible to confirm any causal relationships. It is possible that epidemiological associations between COVID-19 and VTE could be measured and better explained by possible confounding factors, such as simultaneous coinfections, preexisting health conditions, and others.

Keywords

biomarkers; COVID-19; pulmonary embolism; deep venous thrombosis

References

1 Lax SF, Skok K, Zechner P, et al. Pulmonary arterial thrombosis in COVID-19 with fatal outcome: results from a prospective, single-center, clinicopathologic case series. Ann Intern Med. 2020;173(5):350-61. https://doi.org/10.7326/M20-2566. PMid:32422076.

2 Gąsecka A, Borovac JA, Guerreiro RA, et al. Thrombotic complications in patients with COVID-19: pathophysiological mechanisms, diagnosis, and treatment. Cardiovasc Drugs Ther. 2021;35(2):215-29. https://doi.org/10.1007/s10557-020-07084-9. PMid:33074525.

3 Nações Unidas. Novos casos de Covid-19 sobem 4% em 28 dias [site na Internet]. ONU News; 2024 [citado 2025 jan 8]. https://news.un.org/pt/story/2024/01/1826622

4 Valencia I, Lumpuy-Castillo J, Magalhaes G, Sánchez-Ferrer CF, Lorenzo Ó, Peiró C. Mechanisms of endothelial activation, hypercoagulation and thrombosis in COVID-19: a link with diabetes mellitus. Cardiovasc Diabetol. 2024;23(1):75. https://doi.org/10.1186/s12933-023-02097-8. PMid:38378550.

5 Li M, Xiao L, Cai J, et al. Absence of a causal link between COVID-19 and deep vein thrombosis: Insights from a bi-directional Mendelian randomization study. J Glob Health. 2024;14:05001. https://doi.org/10.7189/jogh.14.05001. PMid:38214889.

6 Manolis AS, Manolis TA, Manolis AA, Papatheou D, Melita H. COVID-19 infection: viral macro- and micro-vascular coagulopathy and thromboembolism/prophylactic and therapeutic management. J Cardiovasc Pharmacol Ther. 2021;26(1):12-24. https://doi.org/10.1177/1074248420958973. PMid:32924567.

7 Nägele MP, Haubner B, Tanner FC, Ruschitzka F, Flammer AJ. Endothelial dysfunction in COVID-19: current findings and therapeutic implications. Atherosclerosis. 2020;314:58-62. https://doi.org/10.1016/j.atherosclerosis.2020.10.014. PMid:33161318.

8 Ali MAM, Spinler SA. COVID-19 and thrombosis: from bench to bedside. Trends Cardiovasc Med. 2021;31(3):143-60. https://doi.org/10.1016/j.tcm.2020.12.004. PMid:33338635.

9 Llitjos JF, Leclerc M, Chochois C, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost. 2020;18(7):1743-6. https://doi.org/10.1111/jth.14869. PMid:32320517.

10 Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9-14. https://doi.org/10.1016/j.thromres.2020.04.024. PMid:32353746.

11 Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844-7. https://doi.org/10.1111/jth.14768. PMid:32073213.

12 Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145-7. https://doi.org/10.1016/j.thromres.2020.04.013. PMid:32291094.

13 Yu B, Li X, Chen J, et al. Evaluation of variation in D-dimer levels among COVID-19 and bacterial pneumonia: a retrospective analysis. J Thromb Thrombolysis. 2020;50(3):548-57. https://doi.org/10.1007/s11239-020-02171-y. PMid:32524516.

14 Gonzalez-Fajardo JA, Ansuategui M, Romero C, et al. Mortality of COVID-19 patients with vascular thrombotic complications. Med Clin. 2021;156(3):112-7. https://doi.org/10.1016/j.medcli.2020.10.004.

15 Bikdeli B, Madhavan MV, Gupta A, et al. Pharmacological agents targeting thromboinflammation in COVID-19: review and implications for future research. Thromb Haemost. 2020;120(7):1004-24. https://doi.org/10.1055/s-0040-1713152. PMid:32473596.

16 Brasil. Ministério da Saúde. Vigitel Brasil 2018: vigilância de fatores de risco e proteção para doenças crônicas por inquérito telefônico: estimativas sobre frequência e distribuição sociodemográfica de fatores de risco e proteção para doenças crônicas nas capitais dos 26 estados brasileiros e no Distrito Federal em 2018 [site na internet]. Brasília; 2019 [citado 2025 jan 8]. https://abeso.org.br/wp-content/uploads/2020/01/vigitel-brasil-2018.pdf

17 Brasil. Ministério da Saúde. Saúde Brasil 2018: uma análise da situação de saúde e das doenças e agravos crônicos: desafios e perspectivas [site na internet]. Brasília; 2019 [citado 2025 jan 8]. https://bvsms.saude.gov.br/bvs/publicacoes/saude_brasil_2018_analise_situacao_saude_doencas_agravos_cronicos_desafios_perspectivas.pdf

18 Costa G, Cavalcante FP, Andrade MCS, et al. Estudo Epidemiológico das Internações por Embolia e Trombose Arteriais no Brasil, entre 2019 e 2023. Brazilian Journal of Implantology and Health Sciences. 2025;7(6):737-53. https://doi.org/10.36557/2674-8169.2025v7n6p737-753.

19 Best DJ, Roberts DE. Algorithm AS 89: the upper tail probabilities of Spearman’s Rho. Appl Stat. 1975;24(3):377. https://doi.org/10.2307/2347111.

20 Bauer DF. Constructing confidence sets using rank statistics. J Am Stat Assoc. 1972;67(339):687-90. https://doi.org/10.1080/01621459.1972.10481279.

21 Martinot M, Eyriey M, Gravier S, et al. Predictors of mortality, ICU hospitalization, and extrapulmonary complications in COVID-19 patients. Infect Dis Now. 2021;51(6):518-25. https://doi.org/10.1016/j.idnow.2021.07.002. PMid:34242842.

22 Al-Samkari H, Karp Leaf RS, Dzik WH, et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood. 2020;136(4):489-500. https://doi.org/10.1182/blood.2020006520. PMid:32492712.

23 Thondapu V, Montes D, Rosovsky R, et al. Venous thrombosis, thromboembolism, biomarkers of inflammation, and coagulation in coronavirus disease 2019. J Vasc Surg Venous Lymphat Disord. 2021;9(4):835-844.e4. https://doi.org/10.1016/j.jvsv.2020.11.006. PMid:33188961.

24 Liang K, Fu Y, Kang Y, et al. Clinical features of COVID-19 patients with venous thromboembolism. Clin Appl Thromb Hemost. 2021;27:10760296211013104. https://doi.org/10.1177/10760296211013104. PMid:34169772.

25 Yamashita Y, Hara N, Obana M, et al. Clinical features of venous thromboembolism in patients with coronavirus disease 2019 (COVID-19) in Japan: a case series study. Circ J. 2021;85(3):309-13. https://doi.org/10.1253/circj.CJ-20-1302. PMid:33473096.

26 Saliba OA Jr, Alves AFJ, Matarazzo C, et al. Trombose venosa profunda de membros inferiores em pacientes com covid-19. J Vasc Bras. 2023;27(22):e20230027. https://doi.org/10.1590/1677-5449.202300271.

27 Rocha AP, Sanchez JG. Desenvolvimento de tromboembolismo venoso e seu impacto em adultos hospitalizados com covid-19: revisão sistemática rápida. J Vasc Bras. 2025;24:e20240073. https://doi.org/10.1590/1677-5449.202400732. PMid:40115432.

28 Ishaaya E, Tapson VF. Advances in the diagnosis of acute pulmonary embolism. F1000 Res. 2020;9:1-10. https://doi.org/10.12688/f1000research.21347.1. PMid:32047618.

29 Wu T, Zuo Z, Yang D, et al. Venous thromboembolic events in patients with COVID-19: a systematic review and meta-analysis. Age Ageing. 2021;50(2):284-93. https://doi.org/10.1093/ageing/afaa259. PMid:33201226.

30 Lobbes H, Mainbourg S, Mai V, Douplat M, Provencher S, Lega JC. Risk factors for venous thromboembolism in severe COVID-19: a study-level meta-analysis of 21 studies. Int J Environ Res Public Health. 2021;18(24):12944. https://doi.org/10.3390/ijerph182412944. PMid:34948552.

31 Smilowitz NR, Kunichoff D, Garshick M, et al. C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J. 2021;42(23):2270-9. https://doi.org/10.1093/eurheartj/ehaa1103. PMid:33448289.
 

Submitted date:
05/16/2025

Accepted date:
04/10/2026

Sociedade Brasileira de Angiologia e Cirurgia Vascular (SBACV)"> Sociedade Brasileira de Angiologia e Cirurgia Vascular (SBACV)">
6a592692a953956a703313b9 jvb Articles
Links & Downloads
1677-7301 (Electronic)
J Vasc Bras ©2026 All rights reserved for this website content. Articles follow their own licenses.

J Vasc Bras

Share this page
Page Sections